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Abstract
Large parallel gains in the development of both computational resources as well as sampling methods have
now made it possible to simulate dissociation events in ligand-protein complexes with all–atom resolution.
Such encouraging progress, together with the inherent spatiotemporal resolution associated with molecular
simulations, has left their use for investigating dissociation processes brimming with potential, both in rational
drug design, where it can be an invaluable tool for determining the mechanistic driving forces behind dissociation
rate constants, as well as in force-field development, where it can provide a catalog of transient molecular
structures on which to refine force-fields. Although much progress has been made in making force-fields more
accurate, reducing their error for transient structures along a transition path could yet prove to be a critical
development helping to make kinetic predictions much more accurate. In what follows we will provide a
state-of-the-art compilation of the molecular dynamics (MD) methods used to investigate the kinetics and
mechanisms of ligand-protein dissociation processes. Due to the timescales of such processes being slower than
what is accessible using straightforward MD simulations, several ingenious schemes are being devised at a
rapid rate to overcome this obstacle. Here we provide an up-to-date compendium of such methods and their
achievements/shortcomings in extracting mechanistic insight into ligand-protein dissociation. We conclude with
a critical and provocative appraisal attempting to answer the title of this review.
1 INTRODUCTION
Recent decades have seen enormous gains in the de-
velopment of computational hardware both in general-
purpose computing resources such as graphical process-
ing units (GPUs) and in molecular simulation-specific
hardware.1,2 Together these have pushed the timescales
that are now accessible into a regime where important
biochemical processes can be studied using all-atom
molecular dynamics (MD) simulations. As a result a
widening catalog of biochemical processes have been
studied at the atomistic level,1–16 including the disso-
ciation of ligand-macromolecule complexes.17–20 These
dissociation processes are relevant in various contexts,
including developing a fundamental understanding for
the chemical basis of life processes as well as in the
rational design of drugs.1,21 With respect to the lat-
ter, for instance, MD simulations have been found to
be ever more accurate in predicting the relative binding
free energies ∆∆Gb between families of ligands and/or
receptors (see Table 1 for definitions of ∆∆Gb and other
terms).22–24
In particular, the determination of accurate mecha-
nisms for ligand-protein dissociation processes, which
can happen over a timespan of microseconds to several
hours,25–30 is a classic unresolved biochemical problem.
There are experimental techniques that have been de-
veloped capable of measuring the overall rate constants
for ligand-protein dissociation processes.25 It remains
extremely difficult, however, for such experiments to
glean an atomic residue-by-residue level understanding
of the dissociative mechanism. Much of the complica-
tions – and richness – of the problem arise from the
inherent ever-fluctuating structures, including those of
the protein, ligand and the solvent medium. Further-
more, recently it has been highlighted25,26,31,32 that a
very important aspect of protein-ligand interactions is
the ligand’s residence time in the target protein – in
many systems the residence time, which correlates more
with mechanism, is a much strong predictor of even-
tual function than the thermodynamic affinity, which
correlates more with structure. Often the residence
time is quantified through its reciprocal, the dissocia-
tion rate constant koff (see Table 1). MD simulations
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could, in principle, be ideal vehicles for investigating
these dissociation process with all-atom resolution, but
their relevant timescales lie far past what can be sim-
ulated even with the best computing resources if one
was to use straightforward MD simulations. This is be-
cause complex biochemical processes often involve mul-
tiple metastable states in the presence of high barriers,
while the fast vibrational motions constrain the integra-
tion time step in a MD simulation to femtosecond (fs)
values.
The idea behind this review is to perform a critical ex-
amination of where we stand in the context of using all-
atom MD simulations for studying the dissociation pro-
cess of protein–ligand complexes. This includes the cal-
culation of their association/dissociation rate constants,
the metastable and transition states relevant to the pro-
cess, and various other related biochemical factors. In
order to tackle problems plagued with such extreme rare
events, several specialized methods have been proposed
and used to deal with the long timescales required to
observe the desired rare event in a simulation.33–35 MD
simulations thus act as in silico microscopes revealing
the mechanisms giving rise to the macroscopic rate con-
stant koff still often determined from experiments. It
can provide a full catalog of intermediate and transi-
tion states that are hard to characterize in experiments
due to their transient nature, revealing specific molec-
ular attractions, steric hindrances, macromolecular mo-
tions and water/solvent effects that together give rise to
the measured rate constant. This attribute has the po-
tential of making it an invaluable tool in rational drug
design.
Here we provide a state–of–the–art glossary and
overview of many of the methods that have been pro-
posed for the purpose, highlighting their key underlying
principles, and what we believe to be their key strengths
and weaknesses. In parallel, we provide specific case–
studies demonstrating the use of MD methods for study-
ing the kinetics of ligand dissociation. We finally con-
clude with our summary of the field – which is half parts
optimistic, and half parts concerned that there are many
challenges still to be surmounted. We believe this re-
view should serve as the definitive manual for someone
willing to develop or apply such methods, as well as
for someone just trying to form an opinion on which
method to use for a specific calculation.
Table 1: Definition of important terms.
Term Definition
∆Gb Absolute binding free energy
∆∆Gb Relative binding free energy difference be-
tween two systems
koff Ligand-macromolecule complex dissocia-
tion rate constant
kon association rate constant equaling
e−β∆Gbkoff
x Molecular configuration of ligand-
macromolecule complex
RC Reaction coordinate
2 METHODS
2.1 Unbiased methods
As long as a sufficient number of unbinding events are
observed in an unbiased MD simulation, the dissociation
rate constants and mechanisms are straightforward to
obtain through simple counting. Of course the timescale
problem limits this approach to just ligand-protein com-
plexes that are fast (un)binders, although the intro-
duction of the Anton supercomputer,36,37 which was
designed for and can run MD simulations two or-
ders of magnitude faster than conventional supercom-
puters, has increased the number of association pro-
cesses that can be studied via long unbiased simula-
tions.27,38–40 It remains difficult, however, to use long
unbiased MD for ligand dissociation processes due to
their much slower rates in general.25–27 Dissociations
studied via this brute-force approach are thus con-
strained to just the fastest unbinders. For example,
Huang and Caflisch 41 have investigated the dissocia-
tion of small ligand molecules from the FKBP protein
binding sites through unbiased MD simulations in ex-
plicit water. Pan et al. 42 ran long simulation on An-
ton for the unbinding of several small ligands from the
FKBP protein. In this section, we summarize a number
of methods that do not require the explicit biasing of an
MD simulation. These methods, in one way or another,
are designed to patch several unbiased simulations to
form a picture of the dissociation process. In the au-
thors’ view, it is non-trivial in most of these methods
to truly assess if especially for slow unbinders, such a
process can lead to truly unbiased results (see Sec. 4).
2.1.1 Markov State Models
Markov State Models (MSMs) provide a powerful
framework with which to model the kinetics of biochem-
ical processes. One of its appealing features is that it
models the kinetics through much shorter MD simula-
tions run in parallel,43–45 which in principle helps to
ameliorate the difficulties with calculating kinetic es-
timates of rare events with statistical confidence. In
essence, an MSM is a parametric model for describing
2
the long-time dynamics of a complex system in terms
of transitions between discrete states in configuration
space.45 The parametrization of an MSM then involves
two crucial steps: (a) the definition of the states relevant
to describing the dynamics of interest and (b) calculat-
ing the transition probabilities for interconverting be-
tween these states. An important point to keep in mind
is that MSMs often define thousands of microstates (us-
ing clustering algorithms on MD simulation data) along
some small collection of collective variables. It is then
possible to “stitch” together these short trajectories to
estimate the transition probability matrix between the
states as long as the system is evolving under a Marko-
vian process, where the transitions into future states will
depend just on the system’s current state, regardless of
its past history. This will be true if one is willing to
coarsen the time-resolution of viewing the system, also
called lag time. In practice, approximate Markovianity
is reached if a long enough lag time is chosen, and hence
it is an important part of building a MSM.
Once the transition probability matrix is determined,
its eigenvalues and eigenvectors also provide us infor-
mation of the dynamical properties of the system. Con-
vergence of the eigenvalues with choice of lag time τ has
been the traditional test for ascertaining Markovianity.
There have been several efforts made in improving the
discretization of configuration space into distinct states,
which is the most important and nontrivial step in
building a MSM. For years, people have known that the
best set of states would be the one with the highest bar-
riers separating states. Choosing the best Markov states
is then equivalent to finding out the slowest processes on
the free energy landscape. This criterion guided MSM
building in many studies. Recently, No`e and Nu¨ske in-
troduced a variational analysis for the approximation of
eigenvalues and eigenfunctions of the transition matrix,
called the variational approach to conformational dy-
namics. Another approach using time structure-based
(time-lagged) independent component analysis (tICA)
has also been proposed to construct MSMs. Later on,
Pe´rez-Herna´ndez et. al. have shown that tICA can be
used to provide an optimal solution to the variational
approach to conformational dynamics,46 and hence can
be used to determine the states of MSMs. A crucial
open problem in this sub-field is the use of biased sim-
ulations for constructing MSMs, an area of great active
interest.47,48
2.1.2 Weighted ensemble
Weighted ensemble (WE) uses the idea of resampling to
speed-up the observation of a desired rare event.49–55
In order to initiate a WE calculation, the first step is
to launch an ensemble of trajectories drawn from some
initial distribution in configuration space, P = P (x),
which might be time-dependent or independent.51 Once
a short amount of time has passed the trajectories are
re-evaluated for their progress along the binned config-
uration space, with certain configurations copied and
others eliminated based on a rigorous adjustment of
their weights made to ensure this new sample of con-
figurations will conserve the current value of P (x).51
This resampling in WE thus aims to increase the num-
ber of trajectories visiting the regions of configuration
space with low probabilities. The WE method will then
re-initiate the ensemble of trajectories from the current
configurations and proceed to iterate through the re-
sampling and MD simulation steps until the desired rare
event is observed.51
One important point to consider is that the binning of
configuration space in WE simulations will be specific
to the problem at hand.51 This predefinition of bins
might in turn affect the ideal values of other parameters
such as the time lag between resampling steps.51 It is
also worth mentioning, however, that the bins do not
have to be fixed during the a WE simulation.50–52 For
instance, there exist adaptive WE simulation schemes
allowing the center and the size of bins to change.50
The bins learn to maximize the distance between each
other within the space that has been sampled and will
spread out as more space has been sampled.50
It is also important to mention that the paralleliza-
tion of trajectories in the WE method make extracting
macroscopic rate constants not so straightforward.49,51
This is due to the fact that parallelization decreases
the relaxation time available to each simulation in order
to help the system reach steady-state.51 Bhatt et al. 49
have devised an approach from which steady-state ki-
netic information such as the mean first-passage time
can be calculated however.
2.1.3 Milestoning
The idea behind the milestoning method is to divide
configuration space into several cells56,57 in order to
break down the dynamics of the system into the lo-
cal transitions between adjacent cells.58 In its origi-
nal implementation, the division of configuration space
was performed along an approximate reaction coordi-
nate (RC), with each discretized point along this RC
then defining a 3N − 1 dimensional hypersurface called
a milestone.59 In more recent formulations a milestone
is defined as a dividing surface between two cells.57
The transitions between milestones represent the most
critical event in this class of methods and short MD
simulations in parallel are initiated at a given mile-
stone and stopped when the simulation reaches an ad-
jacent milestone.57–59 These local transition events can
be “stitched” together to recover the long-time kinetic
properties of the rare event process.57,58 It is worth-
while to mention that the choice of milestones have of-
ten satisfied the condition that the transitions between
them are Markovian,56,58 the consequence of being that
the first-passage-time distribution will be independent
of the full history before arriving at a given milestone.
A recent development is the introduction of a formally
exact formulation where the mean first passage time
was derived from exact statistical analysis of the indi-
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vidual local mean first passage times for the functional
transitions between the conformational space cells.57
2.1.4 Adaptive multilevel splitting
In adaptive multilevel splitting (AMS),60 the generic
objective is to calculate the mean first passage time
corresponding to a transition from an initial reactant
metastable state, A, to a final product metastable state,
B. For this AMS aims to estimate the committor prob-
ability, Pc, known to be the exact RC for any arbitrary
reaction, and roughly defined as probability that a tra-
jectory initiated in the reactant state will reach the
product state before returning.61 With the estimated
Pc, the mean first passage time corresponding to a tran-
sition from A to B can be calculated. Although Pc is
the perfect RC, it is important to keep in mind that it is
not known a priori – it is after all the quantity that the
AMS algorithm is attempting to estimate. The AMS al-
gorithm requires that progress along a RC be measured
and an approximate user-defined trial RC z different
than Pc is used for this. The basic AMS algorithm
begins with N initial MD trajectories launched from
a point z = z0, denoting an initial value correspond-
ing to the reactant state A. The MD simulations are
all stopped when the N replicas return to a RC value
z = z0. The next step in the AMS algorithm is to ex-
amine the progress that each replica made in sampling
the RC during the simulation. For this, AMS involves
systematic removal and addition of replica, until the de-
sired rare event from A to B has been sampled and an
estimate of Pc from the product of different conditional
probabilities for moving between different z values can
be calculated. Pc is then directly involved in calculating
the rate constant through a simple expression.60
2.2 Biased sampling based methods
Due to the timescale associated with ligand unbinding
processes often being minutes or longer,25,62 a large
number of studies have sought to introduce biasing
forces into the molecular description of the system to
drive the simulation to sample the process of inter-
est.33–35,63 Care must be taken, however, to do so in a
rigorous manner allowing the statistics of the original,
unperturbed process to be recovered.64 This is relatively
straightforward to do when the aim is to recover static
equilibrium properties such as free energies, but it turns
out to be a much more formidable task when the goal is
to recover, from a biased simulation, the unbiased kinet-
ics, although methods to do so have been developed.65
Unfortunately, the need to introduce bias into molecular
simulations can often be severe when one is interested in
capturing accurate rate constants and associated mech-
anisms. The reason is that several rare events must be
observed in order to obtain kinetic estimates that are
of statistical significance.66 While binding free energies
are state functions that require appropriate sampling
of just the initial and final states22,23 of the desired
biochemical process, the kinetics are path-dependent,
meaning a whole ensemble of transition paths67 must
be sampled before an averaged kinetic estimate can be
produced. Here we summarize one such very popular
method, namely metadynamics, that makes it possible
to get unbiased rate constants and pathways from bi-
ased MD simulations. Note that there are alternative
approaches to adding a biasing potential by increasing
the temperature of the system, either whole or along
parts, for which we refer the reader to another recent
thorough review of methods.62
The metadynamics68 method has been the most pop-
ular of these biasing approaches due to the development
of the infrequent metadynamics framework, which al-
lows unbiased kinetics to be extracted from the biased
simulation using an acceleration factor.65 The basic idea
behind metadynamics is to add a history-dependent bias
potential to the system’s Hamiltonian using a prede-
termined deposition stride, and as a function of a set
of collective variables (CVs) s(x) mapping the high-
dimensional x into a low-dimensional representation.
The bias V (s, t) is typically constructed as a sum of
gaussians deposited along the trajectory in the CV
space. As time goes by, this additional bias prevents
the system from revisiting the same site in the CV
space. The free energy surface (FES) F (s) is then ob-
tained from the negative of the bias potential added. If
the FES is truly well-converged, especially in the bar-
rier regions, then the kinetic rate constants can also
be estimated from the recovered barrier height between
the metastable states by transition state theory (TST).
However, a fundamental issue in using a FES derived
from metadynamics, umbrella sampling or any other
method for rate calculation is that of dynamical cor-
rections to the TST rate.69 The transition rate calcu-
lated by TST is only a crude upper bound to the true
rate, and a transmission coefficient needs to be calcu-
lated for example by launching trajectories from top of
every barrier identified on the FES.
A much simpler method named “infrequent metady-
namics” was proposed to get unbiased dynamics from
biased dynamics which bends around the calculation of
the transmission coefficient by making the assumption
that it is defined only by the properties of the barrier.65
Thus if one could avoid adding bias on the barrier, the
transmission coefficient could be kept same between the
biased and unbiased simulations. Infrequent metady-
namics allows doing this assuming a decent CV is known
for the process being stand. Note that this CV does not
have to be the perfect RC (see Sec. 2.1.4 for descritpion
of committor probability) but can be a simple combi-
nation of order parameters which can be optimized us-
ing preliminary frequent metadynamics runs with the
method SGOOP70,71 Once such a CV is known, infre-
quent metadynamics proceeds by simply decreasing the
bias addition frequency so that the time interval be-
tween two bias addition events becomes slower than
the time spent in the barrier regions, thereby avoid-
ing adding bias there. The unbiased timescale can then
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be obtained from the biased timescale simply through
the calculation of an acceleration factor, which is the
running average of the exponentiated bias given by
α(t) = (1/t)
∫ t
0 e
βV (s)dt where s is the CV being bi-
ased and t is the simulation time. The reliability of the
unbiased dynamics so reconstructed can then be ascer-
tained through a simple p-value test.72 The idea of using
acceleration factor in metadynamics to directly obtain
unbiased kinetic information has also been introduced
in other variants which we do not discuss here.73–76
2.3 Machine learning based methods
Recently, attempts have been made to use machine
learning to ameliorate the timescale problem in all-
atom simulation of biochemical processes.35,77–80 Al-
though these machine learning protocols have been
leveraged in a few different contexts, the most com-
mon approach involves using neural networks trained
to learn a low-dimensional representation approximat-
ing the RC.77–79,81 Finding such low-dimensional RC
representations is often a crucial step in both the bi-
ased and unbiased algorithms we have described. Two
particular approaches have directly employed the neu-
ral network based RC for use in an MSM,77,79,81 or for
use with a biased MD method like metadynamics78 or
umbrella sampling.82 For instance, Mardt et al. 81 sug-
gested the use of two parallel neural networks in con-
junction with the variational principle for Markov pro-
cess (VAMP) to propose VAMPnets,81 which in prin-
ciple can automate the generation of an MSM. Build-
ing an MSM often requires technical expertise on the
part of the investigator and could be an important de-
velopment in increasing the reach of MSM. A different
approach,35,80 which our group has proposed, uses an
unsupervised machine learning method to learn both a
low-dimensional approximate RC as well as a bias po-
tential along this neural network RC, and hence is its
own enhanced sampling method. One interesting fea-
ture of this approach, named Reweighted autoencoded
variational Bayes for enhanced sampling (RAVE),35,80
is that the RC and bias potential are learnt from the
neural network simultaneously, which turns out to be
helpful in screening through spurious machine learning
solutions of the biasing parameters. The RAVE pro-
tocol involves iterating between machine learning and
MD, with each iteration learning a more refined low-
dimensional RC representation and bias potential, these
iterations continuing until these biasing parameters are
converged and sufficient to sample the desired ligand
dissociation. One benefit of this approach is that a
time-independent bias is produced which can be used
to launch multiple independent production MD runs,
which is helpful in extracting statistically robust kinet-
ics information. Thus far, RAVE has been applied to
the benzene-lysozyme complex in order to calculate ab-
solute binding affinities in close agreement with other
enhanced sampling methods.80 In addition, in recent
work that is soon to be published we have applied RAVE
to study the kinetics of ligand dissociation.83
3 CASE STUDIES
3.1 Sub-microsecond unbinders
Huang and Caflisch 41 have studied the dissociation of
six small ligands from the FKBP protein using unbi-
ased MD simulations, which was possible due to their
choice of ligands whose dissociation was expected to
occur in ∼20 ns,41 based on experimental dissociation
constants.84 It was found that the kinetics for these dis-
sociations followed single-exponential kinetics and that
the unbinding times ranged between four and eighteen
ns.41 An interesting result from their work is the obser-
vation that the ligands can take various conformations
at different FKBP binding site positions and that there
exists a heterogeneity of dissociation paths. In addition,
Pan et al. 42 performed long unbiased MD simulations
that were µs in length with the Anton supercomputer
on the same protein (FKBP) with various small ligands
but with a different force-field.42 Several spontaneous
association and dissociation events were observed and
kon and koff estimated. Similar to the conclusion of
Huang and Caflisch 41 , ligand binding to different bind-
ing sites were observed, and multiple dissociation paths
were sampled.42 The reported residence times in 8–140
ns range42 which interestingly is quite different from the
numbers reported by some of these ligands in Ref.41
3.2 Benzamidine-trypsin
The benzamidine-trypsin system has been one of the
most popular systems for simulating the protein-ligand
association/dissociation process using all-atomMD sim-
ulations, starting with the MSM based work in 2011.85
Since then numerous other methods have been applied
in the last few years to study this system, with the only
benchmark86 that has been used in these studies be-
ing a 1970 experimental measurement of koff=600 s
−1.
MSM seem to be systematically overestimating the ex-
perimental rate constant, with predicted koff of 95000
s−1 in 2011,85 28000 s−1 in 201487 and more recently
13000 s−1 in 2015.88 Use of WE method gives 5555
s−1, AMS gives 240 s−1 while metadynamics gives 9
s−1. Thus we have different MD methods giving rates
that range from 160 times faster than experiments to 65
times slower than experiments – or a 4 orders of mag-
nitude variation. This is a strikingly large range, likely
arising from a combination of the use of different force-
fields and different sampling methods. What is however
more re-assuring that many of these different methods
using different force-fields have obtained similar dom-
inant unbinding pathway of this system, with similar
metastable states as defined by the ligand position, ori-
entation, protein conformation, and water molecule lo-
cation. This more pronounced agreement between path-
ways than between rate constants is worthy of further
discussion and is revisited in Sec. 4.
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3.3 Protein kinases
Kinases are arguably the second most important group
of drug targets, after G-protein-coupled receptors. Thus
naturally there has been a strong interest in ap-
plying all-atom MD methods to study the associa-
tion/dissociation of pharmaceutical ligands from pro-
tein kinases. In 2011, the special-purpose supercom-
puter Anton was used to study the association dynam-
ics of the drug Dasatinib to Src kinase38 where they
were able to achieve spontaneous binding of the lig-
and (but not unbinding) in around 1 out of 6 trajec-
tories. They found numerous attractor spots on the
surface of the protein, and the binding process essen-
tially involved navigating the maze of these short-lived
albeit metastable states on the way to the actual bound
pose. They also identified intriguing behavior of wa-
ter molecules during binding, where a single layer of
water molecules (lifetime 0.1 µs) was found to be one
of the many impediments to binding. Later, Tiwary
et al performed infrequent metadynamics simulation of
the unbinding of this same system, where they achieved
full unbinding in 12 out of 12 simulations, identifying
metastable states and their fluxes.89 They also found
waters to play a very critical role. Namely, they found
that a well-preserved Glu-Lys salt bridge had to distort
before the ligand could exit the protein, aided by solvent
water molecules. As we describe in Sec. 4, this finding
has important repercussions for possible use of constant
pH methods in the simulation of drug unbinding. The
calculated association and dissociation rate constants
from the Anton and metadynamics simulations respec-
tively were in good agreement with experiments, and
perhaps more significantly, with each other. In a sim-
ilar vein, Casasnovas et al have applied metadynamics
to study unbinding of urea-based BIRB family inhibitor
from p38 kinase.90 In this last work, they performed
metadynamics using two different sets of CVs, and us-
ing the self-consistent measure of Ref.,72 they were able
to select one of these as reliable. The koff value from
this agreed well with experiments, demonstrating the
usefulness of the test from Ref.72 in ascertaining the re-
liability of dynamics reconstructed from metadynamics.
3.4 Heat shock protein 90
Heat shock protein 90 (HSP90) is a chaperone protein
generally found in all bacterial and eukaryotic cells, and
inhibitors of HSP90 have strong potential to be used as
anti-cancer drugs. However, the presence of various con-
formational states and flexibility of the HSP90 protein
at the binding site makes the investigation of kinetics
very challenging.91 Mollica et al. used the smoothed-
potential MD or scaled MD which is essentially an ap-
proximate and computationally efficient version of in-
frequent metadynamics, with the intent to focus more
on relative dissociation rates rather than absolute rates.
They used this to study dissociation of several ligands
from HSP90 and obtained agreement with reported ex-
perimental results. In a somewhat similar vein, Random
acceleration molecular dynamics (RAMD) method has
also been used to study binding/unbinding pathways
of various proteins92,93 and calculate relative residence
times for a set of various ligands to the N-terminal do-
main of the HSP90, finding good agreement with re-
ported results.
3.5 G protein–coupled receptors (GPCRs)
G protein–coupled receptors (GPCRs) are of tremen-
dous pharmacological importance, with ∼50% of all
drugs on the market designed to act through modula-
tion of GPCRs.94 GPCRs are trans-membrane proteins
comprised of seven α-helices and have the critical cel-
lular function of controlling the cells response to the
presence of extracellular molecules. Due to both their
fundamental and practical importance it is desirable to
investigate the dynamics of GPCRs using all-atom MD.
Using unbiased MD on the Anton supercomputer, Dror
et al. studied the binding of antagonists and agonists to
the β2 adrenergic receptor,
17 observing twelve binding
events leading to a kon estimate of 3.1×10
7 M−1s−1,
which is in good agreement with the experimental value
of 1.0×107 M−1 s−1. Notice however that the abso-
lute koff has not been calculated for GPCR-ligand com-
plexes, although Mollica et al. 95 used the dissociation
process in order to rank four different triazine-based lig-
ands according to their residence times, relative to a ref-
erence. Good agreement with experimental results was
reported.95 In addition, Bortolato et al. 75 determined
whether a series of ligands were fast or slow using their
recent technique named adiabatic–biased metadynam-
ics (aMetaD) in conjunction with an approximate resi-
dence time score. In more recent work, Meral et al. 96
used Metadynamics with a Maximum Caliber approach
and reported that thermodynamic properties as well as
kinetic properties can be achieved for GPCR activation.
3.6 HIV-1 protease
The HIV-1 protease contains two β-hairpin loops called
flaps whose dynamics, according to different stud-
ies,97,98 play an important role in the mechanisms of lig-
and association and dissociation from the binding pock-
ets. For this reason the HIV-1 protease is a challenging –
and interesting – system for MD simulations. Focusing
on investigating the mechanism of binding for a pep-
tide with HIV-1 protease, Pietrucci et al.99 employed
the bias-exchange metadynamics (BEMD) method and
captured important features of the mechanism such as
water bridges, conformational changes of the flaps, var-
ious important interactions between the ligand and pro-
tease. They calculated the kinetics from a 7-dimensional
order parameter space through a weighted histogram
method and the kon and koff values were in rough
agreement with the available experimental results. Sun
et al.100 studied kinetics for 6 systems including HIV
protease complexed with the drug lopinavir using infre-
6
quent metadynamics, finding decent overall agreement
in rate constants.
4 CONCLUSIONS: ARE WE
THERE YET?
In this short review we have described some of the meth-
ods useful for calculating the kinetics, and more gen-
erally the mechanisms, of ligand-protein dissociations
from all-atom MD simulations, and highlighted some of
their successes and shortcomings with case-studies. A
clear message which is embedded throughout is that the
use of MD simulations to investigate ligand-protein dis-
sociations is brimming with potential and could soon
have a significant impact in the rational design of drugs
and in understanding biochemical processes fundamen-
tal to life. This is because MD simulations complement
experimental kinetics in a natural way, since they pro-
vide a wealth of experimentally difficult-to-get mecha-
nistic information. This being said, there are large ob-
stacles remaining for unleashing the full potential of MD
simulations to practical applications. The first obstacle
is the inherently limited timescales that can be attained
in all-atom MD simulations. We have highlighted here
a number of ingenious MD methods that have been de-
vised to deal with this limitation. This sampling prob-
lem is coupled to identifying a good RC, which we would
like to argue is a limitation in the biased but also the
unbiased methods, even thought it might not be obvious
for the latter class of methods. Recent years have shown
signs of hope in this RC problem through the develop-
ment of many automated methods.35,70,101,102 A second
problem is the force-field issue. Due to the large number
of atoms involved in biochemical systems, an analytic
model, called force-field, describing the energy interac-
tions between the constituents must be used. These
models often are based on available structural and ther-
modynamic data, which tends to be richer in describ-
ing longer lived metastable structures. Keep in mind,
however, that kinetic estimates depend on sampling a
whole ensemble of transition paths which necessarily
venture outside these data-rich regions. The careful
cataloging of the transition states describing rare event
processes should find use in helping refine the available
force-fields, which would lead to better estimates from
MD simulations since the predictions stemming from
MD simulations depend on the accuracy of the force-
field used to model the microscopic interactions between
these atoms. In a sense, these two limitations are cou-
pled – developing force-fields that better characterize
not just thermodynamic but also kinetic data essen-
tially needs development of reliable sampling methods
that can deal with long timescales.
In fact, one crucial metric that is missing thus far
is the degree to which the errors in sampling are de-
coupled from the force-field errors. The benzamidine–
trypsin case study serves as a perfect example, with
different methods using different force-fields producing
dissociation timescales differing by a staggering four or-
ders of magnitude, even though somewhat reassuringly,
many of these studies have discovered similar dissoci-
ation pathways and crucial intermediate states. Both
could be significant in deviations of kinetic predictions
from experimental values. A thorough, systematic in-
vestigation of how the same MDmethods handle the dif-
ferent available force-fields for the same systems would
be invaluable in providing a sound estimate of the er-
rors from force-fields relative to the sampling. This will
help in establishing how valid it is to compare koff and
kon values directly with experiments. An important
example of this is the different water models used in
force-fields, which can lead to water diffusivities that
are three to four times as different.103 Similarly, yet
another parameter which has not received much men-
tion in typical MD based publications for calculating
dissociation timescales and mechanisms is the friction
coefficient used in the simulation in order to maintain
desired temperature. This coefficient can also have pro-
found effects on the calculations through what is known
as the Kramers’ turnover phenomenon.104,105 Such dif-
ferences can significantly affect the calculated rate con-
stants and even lead to agreement between experiments
and simulations for wrong reasons. Finally, we would
like to highlight that some of the slowly dissociating
systems have also been found through all–atom simula-
tions to show salt–bridge distortions and thus possible
protontation state dependence.89,106,107 This hints on
the usefulness of constant pH simulations in the study
of dissociation mechanisms. To conclude, all-atom MD
simulations go beyond giving just a rate constant – they
hold the promise of giving pathways and unambiguously
highlighting the role of individual players such as spe-
cific residues and individual water molecules. Much
progress has been made in this field, but a long way
remains before all-atom MD simulations can be deemed
truly complimentary and even predictive of actual ex-
periments of ligand–protein dissociation processes.
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